Study: Fragile Histidine Triad Merits Further Focus in Mesothelioma Treatment Research

The role of fragile histidine triad protein expression in pathogenesis of malignant pleural mesothelioma has been the focus of a study reported in the journal Pathology, in February 2008. Researchers investigated the relationship of fragile histidine triad (FHIT) and Ki-67 expression with clinicopathological variables of patients with malignant pleural mesothelioma (MPM). The authors, Tutar and Kiyici, conclude that their results support the role of FHIT as a tumour suppressor gene in asbestos induced MPM. They write that there is no significant correlation between FHIT and cell proliferation marker expressions in malignant pleural mesothelioma. Therefore, they conclude, the loss of FHIT apparently does not interfere with tumour proliferation. This can be accepted as evidence for an early role of FHIT loss in carcinogenesis; however, in fulfillment of the scientific method, their results must be strengthened by further studies.

Source - Asbestosland.com

To contact one of our specialist lawyers please call 0800 61 66 81, or use the contact details at the top left of this page.